ASH Clinical News December 2015 | Page 73

RESIDUAL DISEASE IN
1-5
MYELOMA GOES DEEP.
COULD A SUSTAINABLE TREATMENT
APPROACH HELP US GO DEEPER?
Hear from myeloma experts and explore
critical debates in multiple myeloma today.
GAIN NEW DEPTHS OF UNDERSTANDING AT
DEBATINGMYELOMA.COM

REFERENCES: 1. Munshi NC, Anderson KC. Minimal residual disease in multiple myeloma. J Clin Oncol. 2013;31(20):2523-2526. 2. Rawstron A, Child JA, de Tute RM, et al. Minimal residual
disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540-2547.
3. Paiva B, Vidriales MB, Cerveró J, et al; on behalf of GEM/PETHEMA Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple
myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-4023. 4. Biran N, Ely S, Chari I. Controversies in the assessment of minimal residual disease
in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques. Curr Hematol Malig Rep. 2014;9(4):368-378. 5. Martinez-Lopez J, Lahuerta
JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073-3079.

Takeda Oncology and
are registered trademarks of Takeda Pharmaceutical Company Limited.
Other trademarks are the property of their respective owners.
Copyright © 2015, Millennium Pharmaceuticals, Inc.

All rights reserved.

Printed in the USA

USO/NON/15/0257(1)

10/15